Getting real-world evidence to the sponsor before the deadline, not after

Real‑world evidence only counts if it reaches the decision‑maker before the window closes.

When a non-interventional breast cancer study needed its interim analysis 10 days ahead of a tight plan, the TFS HealthScience oncology team did not add people or push back on the ask. They changed how the team worked.

In this case study you will discover:

  • Why the solution had nothing to do with headcount
  • How the team structure made the difference
  • What the outcome looked like across every deliverable

Download the case study to see how the team delivered.

Connect with Us

Contact us today to discover how TFS can be your strategic CRO partner in clinical development.

Let's Talk

Latest Oncology Resources

Insights from ASCO 2025: Oncology Clinical Trial Trends CROs and Sponsors Need to KnowArticle

Insights from ASCO 2025: Oncology Clinical Trial Trends CROs and Sponsors Need to Know

Explore key takeaways from ASCO 2025, from ctDNA and AI to novel biologics and inclusive trials. Learn how to stay ahead in oncology research.
Rare-Disease-Day-2025-How-Precision-Medicine-is-Transforming-Treatment-for-Rare-Diseases_featured
Rare Disease Day 2025: How Precision Medicine is Transforming Treatment for Rare DiseasesArticle

Rare Disease Day 2025: How Precision Medicine is Transforming Treatment for Rare Diseases

Explore how precision medicine is revolutionizing rare disease treatment through targeted therapies, gene editing, and AI-driven solutions.
Revolutionizing-Oncology-Trials-The-Power-of-Immunotherapy-and-Precision-Medicine-in-Cancer-Research_featured
Revolutionizing Oncology Trials: The Power of Immunotherapy and Precision Medicine in Cancer ResearchArticle

Revolutionizing Oncology Trials: The Power of Immunotherapy and Precision Medicine in Cancer Research

A comprehensive guide exploring the challenges and best practices in cancer immunotherapy clinical trials.